Debt-to-equity in % of Calidi Biotherapeutics, Inc. from Q2 2022 to Q3 2025

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Calidi Biotherapeutics, Inc. quarterly Debt-to-equity history and change rate from Q2 2022 to Q3 2025.
  • Calidi Biotherapeutics, Inc. Debt-to-equity for the quarter ending 30 Sep 2025 was 199 %.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Change (%)

Calidi Biotherapeutics, Inc. Quarterly Debt-to-equity (%)

Period Value YoY Chg Change % Date
Q3 2025 199 30 Sep 2025
Q2 2024 -219 -184 -525% 30 Jun 2024
Q1 2024 -83 -44.9 -118% 31 Mar 2024
Q4 2023 -45.9 -0.28 -0.61% 31 Dec 2023
Q3 2023 -49.3 -15.7 -46.8% 30 Sep 2023
Q2 2023 -35.1 +13.4 +27.7% 30 Jun 2023
Q1 2023 -38.1 31 Mar 2023
Q4 2022 -45.7 31 Dec 2022
Q3 2022 -33.6 30 Sep 2022
Q2 2022 -48.5 30 Jun 2022
* An asterisk sign (*) next to the value indicates that the value is likely invalid.